Abstract: Sigma receptors have been implicated in a myriad of cellular functions, biological processes and diseases. While the precise biological functions of sigma receptors have not been elucidated, recent work has shed some light on to these enigmatic systems. Sigma receptors have recently been a target of drug development related to psychiatric and neurological disorders.
A. INTRODUCTION TO SIGMA RECEPTORS
Sigma receptors, first thought to be a type of opiate receptor, were first discovered in 1976 by William Martin through his evaluation in the chronic spinal dog model [1] . Over time, pharmacological and behavioral studies revealed that these sites are not part of the opiate receptor system but are in fact distinct from all previously characterized mammalian proteins [2, 3] . Two sigma receptor subtypes are currently recognized and are termed sigma-1 and sigma-2. A third subtype had been proposed and a pharmacophore model developed [4] , however further research indicates that the ligands used to identify these putative sigma-3 sites were a new class of compounds that bind to the H(1) site [5] . The best characterized subtype is the sigma-1 receptor, while quite a bit less is known about the sigma-2 site. For this reason, much of this review focuses in the sigma-1 receptor subtype.
The human sigma-1 receptor has been cloned [6] . It is a single transmembrane receptor consisting of 223 amino acids located on the outer cell membrane and the endoplasmic reticulum. The σ-1 receptor is structurally unrelated to the *Address correspondence to this author at the Siemens Biomarker Solutions, 406 Industrial Drive, North Wales, PA, 19454, USA; Tel: 215-699-9053; Fax: 781-459-0277; E-mail: LeeCollier@mac.com known mammalian proteins but is homologous in structure to fungal proteins involved in sterol biosynthesis, including yeast sterol isomerase [6, 7] . The gene (~7 kbp long) for the human σ−1 receptor is located on human chromosome 9, band p13, a region known to be associated with many psychiatric disorders, including schizophrenia, paranoid psychosis and personality disorder [8] . The gene contains a cytokine responsive element and a steroid responsive element. Sigma-1 receptors are likely G-coupled, although this aspect is not unchallenged [9] .
Electrophysiological studies strongly indicate that sigma ligands modulate NMDA-induced neuronal activation of CA3 pyramidal neurons, as well as influence the firing rate of A9 and A10 dopaminergic neurons [2, 3, [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Such effects are not obviously due to binding at dopamine D1, D2, NMDA, PCP or NMDA associated glycine receptors. Compounds are designated as sigma-1 agonists if they selectively potentiate NMDA mediated neuronal activity without altering kainate and quisqualate induced activations [23] . Antagonists do not modify NMDA induced firing on their own, but suppress the potentiation induced by sigma-1 receptor agonists. There is strong pharmacological and behavioral evidence that the endogenous ligands for the sigma-1 receptor subtype include certain neuroactive steroids [11] . In particular, dehydroepiandrosterone (DHEA) is a sigma-1 receptor agonist, whereas progesterone is a sigma-1 receptor antagonist. Testosterone also binds sigma-1 receptors with high affinity [24] . The binding of these steroids to sigma receptors and the implications of this to the pharmacology and imaging of these sites is discussed in more detail below.
Much less is known about the pharmacology of sigma-2 sites, and therefore agonist induced responses associated with this protein are not currently defined. Sigma-2 sites have been linked to cellular proliferation processes, reported to be more highly expressed in highly proliferating cells [12, 13] . More recently sigma-2 receptors have been associated with apoptosis [25] [26] [27] . Both sigma-1 and sigma-2 sites are found in high densities in a wide variety of human tumors, including those of the breast, lung, colon, ovaries and prostate [28] [29] [30] . For example, in a breast cancer cell line sigma receptors are found in high densities (MCF-7 cells, Bmax = 2071 fmol/mg protein; and T47D breast ductal carcinoma cells, Bmax = 1221 fmol/mg protein) [28] . As is discussed below, the involvement of sigma-2 receptors in tumor cell proliferation has lead to research into imaging these sites to report on tumor status and to the development of anti-cancer drugs that bind these sites. Several reviews on sigma receptor drug development [31] , pharmacology [32] [33] [34] [35] [36] , and potential clinical applications [37] [38] [39] have been written. This review will focus on applications of imaging sigma receptor subtypes noninvasively by positron emission tomography (PET) or single photon emission computed tomography (SPECT), and the development of the radioligands required. Included are applications in the fields of neurology, psychiatry, cardiology and oncology.
B. CLASSES OF DRUGS THAT BIND SIGMA RECEP-TORS Compounds that Bind Sigma Receptors Represent Many Different Structural Classes
Examples are included in Fig. (1) and illustrate the various structures of high affinity sigma receptor binding ligands. Most compounds assessed to date demonstrate selectivity for the sigma-1 receptor over the sigma-2 subtype. The diversity of structures that interact with these sites has caused confusion over their biological roles and pharmacological significance. Early on it was discovered that many typical antipsychotic drugs bind sigma receptors, and therefore hypotheses regarding their roles in both the therapeutic [40] [41] [42] and side effects [43] were put forth. Several papers describe in detail the sigma receptor pharmacophores and the different sigma receptor drug classes [4, [44] [45] [46] [47] , so this will not be reviewed further here.
C. DEVELOPMENT OF SIGMA RECEPTOR RADIO-LIGANDS
The fact that high densities of sigma receptors have been measured in human cancer cell lines prompted several laboratories to develop sigma receptor targeted radioligands (some characteristic radioligands are shown in Fig. 2 tumor xenografts [49, 54, 65] . It was furthermore demonstrated that in vitro binding of this class of compounds in cell membranes correlates with proliferative status, suggesting an up-regulation of sigma binding sites prior to mitosis [66] . Caveliers [57] . A tumor associated increase in radioactivity was observed in 8 of 10 patients with histologically confirmed breast cancer (mean tumor-to-background ratio, 2.04). The authors conclude that [ 123 I]PMBA accumulates in most breast tumors in vivo. However, the tumor uptake of the benzamide class of tracers has not been clearly proven to be entirely mediated by sigma receptor expression. For example, Eisenhut et al. [67] used differential and equilibrium density-gradient centrifugation to reveal that most of the radioactivity from the closely related tracer [ 123 I]IMBA was associated with fractions containing melanin granules. This of course subsequently complicates the interpretation of in vivo information obtained using these agents. [50] . Studies in mice bearing MDA-MB231 breast tumor xenografts revealed selective tumor uptake (3.8% ID/g) at one hour post-injection with tumor/muscle and tumor/blood ratios of 6.2 and 7.0, respectively. The uptake of radioactivity was blocked by preadministration of haloperidol. Despite promising preliminary results, no subsequent evaluations of this tracer have been reported. Another interesting fluorine-18 labeled radiotracer, [ 18 F]N-(4'-fluorobenzyl)-4-(3-bromophenyl)acetamide, with high affinity for both sigma-1 and sigma-2 subtypes was recently reported by Mach and colleagues [13] . This tracer is also in early stage preclinical evaluation.
Waterhouse and colleagues have focused on the development of a piperidine-based class of sigma-1 receptor selective radiotracers for imaging these sites in malignancies, and in the primate brain [51, 52, 61, 63, [68] [69] [70] [71] [72] [73] . A total of 38 compounds have been examined in vitro for receptor binding affinity, selectivity and appropriate lipophilicity. As an initial test model, black mice with B16 melanoma xenografts were used to characterize six promising radiolabeled derivatives of this series with appropriate in vitro properties (Ki (sigma-1) values between 0.1 and 5 nM; log P from 1. Fig. 2 ). [75] are the most selective sigma receptor tracers that have been administered to humans (see Fig. 2 ). The evaluation of these tracers for imaging sigma-1 receptors is ongoing.
D. POTENTIAL SIGMA RECEPTOR MEDICATIONS CURRENTLY BEING EVALUATED IN CLINICAL TRIALS [76]
A recent search of the European Patent service (ep. espacenet.com/espacenet/ep/en/e_net.htm) gave a result of over 200 patents and Patent Cooperation Treaty (PCT) applications for various applications of agents that bind to sigma receptors. The claims in these documents include:
• Sigma ligands can modulate endothelial cell proliferation and can control angiogenesis.
• Sigma antagonists could be used to inhibit angiogenesis and treat conditions such as psoriasis, diabetic retinopathy and cancer. [14-22, 33, 77-99] , stating that it acts through cell signaling technology based upon the sigma receptor. This company has a specific core area of research focused on the neurobiology of sigma receptors. Furthermore, they put forth that this receptor system offers a new way to treat major depression, dementia and drug abuse. This lead compound has completed phase I clinical trials and will be starting a Phase II trial as an antidepressant.
AGY Therapeutics (South San Francisco, CA, USA) is investigating AGY-94806 (also known as M's Science compound SA4503) started a Phase II clinical study with stroke patients for enhanced functional recovery from stroke.
Otsuka American Pharmaceutical (Rockville, MD) currently is developing OPC-14523, a mixed 5-HT 1A (IC 50 = 2.3 nM)) and sigma-1 agonist (IC 50 = 47-56 nM) that has entered into Phase II clinical studies for use in depression [100, 101] . VPI-013 (also known as Otsuka compound OPC-14523) Sanofi-Synthélabo has developed a sigma receptor antagonist named ISR 31747 that is currently in Phase II clinical trials for the treatment of rheumatoid arthritis. In addition, SR31747 has demonstrated immunosuppressive properties, preventing the development of acute graft-versus-host reaction (GvHR) in hybrid B6D2F1 mice injected with C57BL/6 parental spleen cells [102, 103] . Anti-proliferative effects have also been noted for SR31747. Sanofi claims that this compound modulates the central sigma receptor, being a potent and very specific antagonist. They are also pursuing its use as a treatment for schizophrenia but it has not yet entered clinical trials for this application. The Sanofi-Aventis drug, SSR 125047, a sigma receptor antagonist has entered clinical trials for the treatment of psychosis.
E. PSYCHIATRIC APPLICATIONS OF SIGMA RECEPTORS

Distribution of Sigma Receptors in the Central Nervous System
In vitro autoradiographic studies have revealed high densities of sigma receptors in many regions throughout the rat, mouse, guinea pig, non-human primate and human central nervous systems [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] . In rats, the highest densities are in the hippocampus and cortex, but they are also abundant in most other brain regions, including the limbic system, cerebellum, striatum, medulla, brain stem, substantia nigra, and spinal cord. In non-human primates, sigma receptors are enriched in paralimbic belt cortices, including the orbitofrontal, cingulate, insula, parahippocampal and temporopolar gyri. They are also concentrated in the medial and central nuclei of the amygdala and within the hippocampal formation. The localization of sigma receptors in the primate limbic system suggests that they may be involved in emotion and memory [108] . Lower, more moderate densities, are found in the ventromedial sectors of the caudate and putamen. In humans, similar distribution occurs, with slightly higher levels of binding (using [ 3 H]DTG), in the substantia nigra pars compacta, cerebellum and neocortex, and moderate levels in the hippocampus and striatum [116, 117] . In reviewing the distribution between species, sigma receptors are found throughout the CNS but the relative regional brain concentrations differ somewhat between mice, rats, non-human primates, and humans.
Neurochemical, electrophysiological and behavioral data support that sigma-1 receptors modulate dopamine release and metabolism in the frontal cortex, striatum, and nucleus accumbens in rodents [2, 3, 6-8, 10-13, 28, 54, 118] . Some ligands of the NMDA receptor, including MK-801 and PCP, can cause psychotomimetic effects in rodents and primates, as do sigma ligands. Many psychotomimetic benzomorphans bind to both the PCP NMDA site as well as to sigma receptors, and this has lead to the hypothesis that these sites are closely related [119] . Evidence has been put forth in recent years to support that sigma receptors either directly or indirectly modulate NMDA neurotransmission. Electrophysiological studies have shown that sigma ligands modulate NMDA-induced neuronal activation of CA3 pyramidal neurons, as well as influence the firing rate of A9 and A10 dopaminergic neurons, and that these effects are not due to binding at dopamine D1, D2, NMDA, PCP or NMDA associated glycine receptors [2, 3, [6] [7] [8] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . As noted earlier, compounds are normally termed sigma agonists if they potentiate NMDA induced firing activity of CA3 pyramidal neurons without altering kainate and quisqualate induced activations [23] . Antagonists do not modify NMDA induced firing, but suppress the potentiation induced by sigma agonists.
Modulation of the glutamate and dopamine systems by sigma-1 receptors in vivo appears to be complex and likely involves both inter-and intra regional mechanisms. Therefore, as in other systems, direct comparisons between in vitro and in vivo data are difficult. However, in vivo experiments using systemically or locally injected sigma ligands perhaps provide the most relevant data as to how sigma agonist or antagonist will induce pharmacological and behavioral changes. In light of this, some promising effects have been reported in several rodent models used to characterize antipsychotic drugs. One specific example is the highly selective sigma-1 agonist SA4503 that increases dopamine turnover rates selectively in the medial frontal cortex, but not in the striatum, substantia nigra or other regions in freely moving rats [18] . This induced increase in dopamine utilization is blocked by administration of the selective sigma-1 antagonist NE-100. Also of interest is that several selective sigma-1 antagonists, such as NE-100, SR37142, XJ448 and MS-377, which modulate dopamine release in the frontal cortex in rodents, have demonstrated promising effects in behavioral models of schizophrenia [120] [121] [122] [123] [124] . NE-100 has a particularly interesting behavioral profile as it 1) attenuates the effects of PCP in a rat diving model; 2) attenuates PCP induced impairment of avoidance inhibition and partially overcame the PCP induced ataxia and decreased attention in monkeys and dogs; 3) completely blocked enhancement caused by sigma agonists on MK 801 induced hyperlocomotion in monoamine depleted mice; 4) attenuated phencyclidine-induced delayed cognitive dysfunction in rats. NE-100 is highly selective for sigma receptors and has negligible affinity for dopamine and serotonin receptors.
Neurosteroid Modulation of NMDA Stimulated Dopamine Release is Mediated via Sigma-1 Receptors
Over the past few years, evidence has been gathered to support the existence of fast, non-genomic actions of steroids in the modulation of neurotransmitters in the mammalian brain [125, 126] . It is proposed that these steroid effects are mediated through cell surface membrane receptors that are most likely G-coupled. Such interactions could be important in maintaining the normal balance of neurotransmitters in the brain, and any disruption in such a system could, in theory, cause behavioral abnormalities. Of interest is that the human sigma-1 receptor gene contains a steroid binding component, and several gonadal steroids, including progesterone, testosterone and dehydroepiandrosterone (DHEA), interact with sigma-1 receptors. There is now strong pharmacological, electrophysiological and behavioral evidence that certain steroids are endogenous ligands for the sigma-1 receptor [24, [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] . Of the steroids examined thus far, progesterone is known to bind with the highest affinity to human sigma-1 receptors, with a reported affinity (Ki) as high as 30 nM. Of importance is that progesterone has recently been shown to modulate NMDA evoked [ 3 H]dopamine release from rat striatal slices in vitro in a dose-dependant manner [138] [139] [140] .
Also reported is that dehydroepiandrosterone (DHEA) potentiates NMDA response via sigma receptors and this effect is suppressed by progesterone and testosterone. Therefore, DHEA acts as a sigma receptor agonist, and progesterone and testosterone as antagonists [129, 130, 141, 142] . It is noteworthy that DHEA is currently being examined in clinical trials to treat patients with schizophrenia, where selective alleviation in negative symptoms is being documented [143] .
Blocking studies using the sigma-1 selective radioligand [ 3 H]SKF-100,047 have provided direct evidence for progesterone binding the sigma-1 receptor in vivo. In the mouse forebrain, binding of [ 3 H]SKF-100,047 was significantly reduced (20-40%) by the in vivo administration of progesterone in doses of 10-40 mg/kg [132] . In addition, a separate study showed that [ 3 H]SKF-100,047 binding was altered when the levels of endogenous progesterone were modified by castration/adrenalectomy in conjunction with enzymatic manipulation [135] . As expected, [ 3 H]SKF-100,047 binding in the brain was increased by decreasing progesterone levels and decreased when progesterone levels were increased. The well-controlled manipulation of progesterone levels in this model also effected sigma-1 receptor mediated behavior of the mice, which included changes in cognitive function and learning deficits.
Using the selective sigma-1 receptor tracer [
18 F]FPS, Waterhouse et al. have demonstrated that progesterone, testosterone and DHEA bind the sigma-1 receptor in vitro and in vivo [144] . Binding affinities were determine in vitro and the effect of iv co-administration of progesterone (10 mg/kg), testosterone (20 mg/kg) and DHEA (20 mg/kg) on in vivo [ 18 F]FPS binding was examined via biodistribution studies in male rats (See Table 1 ). Inhibition constants (Ki) determined for the steroids progesterone, testosterone and DHEA were, 36, 201 and 706 nM, respectively. The affinity order of these compounds is the same as previously reported for sigma-1 receptors [145] . In vivo administration of progesterone, testosterone or DHEA significantly decreased [
18 F]FPS uptake (%ID/g) by up to 50% in nearly all brain regions examined ( Table 1) .
[ 18 F]FPS uptake in peripheral organs that express σ receptors (heart, spleen, muscle, lung) was also reduced (54-85%), while blood activity values were not significantly different. These studies indicate that this tracer might provide an effective tool for studying the effects of neuroactive steroid administration on human brain function.
Sigma Receptors and Schizophrenia
Haloperidol is one example of many typical antipsychotic agents that possesses high affinity for sigma receptors. Haloperidol is reportedly an antagonist at both sigma-1 and sigma-2 receptors. As with all typical neuroleptics, in addition to its therapeutic effects, haloperidol also induces unwanted motor effects in patients, and initially its binding to σ receptors was thought to contribute to the unwanted motor side effects of typical neuroleptic treatment. However, subsequent studies to evaluate more highly selective sigma-1 receptor ligands in rodents, monkeys and humans has indicated that this receptor is likely not responsible for the unwanted motor effects of these compounds. To date, the role of sigma-2 sites in unwanted motor effects has not been ruled out. Indeed, many potential antipsychotic agents with atypical therapeutic profiles in rodent models and humans bind sigma-1 receptors with moderate to high (nM) affinity. Examples include rimzacole [146] , remoxipride [147] , BMY 14802 [147] , NE-100 [120, 123, 124, [148] [149] [150] [151] [152] [153] [154] , panamisine (EDM 57445) [122, 155, 156] , and SL82.1705 [157] . Perhaps selective binding to this site is not enough to alleviate symptoms, but it is possible that a drug with mixed sigma receptor binding and activity at other receptors or transporters might be appropriate. Such possibilities are being explored, although this is a complex problem.
To date, most potential antipsychotic drugs that have been tested in humans are rather non-selective and would be expected to interact with several receptor subtypes when administered at therapeutic doses. Other compounds suffer from fast metabolism or low sigma receptor affinity. One example, BMY 14802 has high affinity for sigma-1 (antagonist), 5-HT 1A , 5HT 2 and dopamine D 4 receptors. Despite its positive pre-clinical pharmacological profile in pharmacological and electrophysiological models, BMY 14802 was found to be ineffective in the treatment of schizophrenia in a study in which 28 patients received up to 3 grams/day for up to four weeks [147] . Two possible reasons for the lack of efficacy of this drug exist. First, BMY 14802 is not selective for σ receptors and its binding to other neuroreceptors may mask any therapeutic sigma receptor related effects. Secondly, PET studies in baboons using [ 18 F] BMY 14802 revealed that this ligand did not have the brain uptake profile expected from a sigma-1 ligand, and fast metabolism and clearance from the brain was also noted [158] . This is in contrast to the profile of haloperidol and other sigma receptor binding radiotracers, which by PET studies exhibits prolonged retention in the CNS [159, 160] . SL 82.0715 is a high affinity sigma agonist possessing low affinity for serotonin and dopamine receptors. In preclinical tests the compound showed antipsychotic properties in rodent models of spontaneous conditioned behavior, with no adverse motor effects such as catalepsy [157] . It exhibited no psychotomimetic properties. An open dose-range study was held to evaluate SL 82.7015, ten chronic schizophrenic patients with predominantly negative symptomology were treated with an increasing dose (2.5-10.0 mg/day). Four patients showed improvement of negative symptoms, two patients deteriorated with regards to positive symptoms, and two remained unchanged. No extra-pyramidal symptoms or other side effects occurred. Subsequent open trials with larger patient numbers are underway to further evaluate this compound.
Panamesine (EMD 57445) is another high affinity, highly selective sigma receptor ligand that, in pre-clinical behavioral studies, exhibits antipsychotic effects and is free of extra-pyramidal motor effects. A 1997 open clinical trial, 5/12 patients were judged as responders (50% decrease in the BPRS score), six patients showed only slight improvement in symptoms, and one deteriorated [155, 156] . No major side effects were observed. A second study was subsequently performed, in which 12 patients received 60 mg/kg per day for 4 weeks [161] . Seven patients completed the study: four were responders, two improved slightly and one deteriorated. At these doses, however, some extra-pyramidal side effects were noted, which were attributed to a metabolite having D 2 antagonistic properties.
Recently, two very selective sigma receptor agonists and antagonists exhibiting good preclinical profiles in behavioral models (NE-100 and SR31742) have entered clinical trials [120, [122] [123] [124] 154] . Clinical trials to evaluate highly selective sigma receptor antagonists and agonists, devoid of metabolites that induce unwanted pharmacological responses (i.e. interactions at dopamine receptors), must be carried out before the efficacy of these agents in the treatment of schizophrenia can be fully assessed. The preclinical and clinical evidence obtained thus far indicates that highly selective sigma-1 ligands may provide some therapeutic benefits for, in particular, the negative symptoms without causing unwanted motor effects. This is important because the vast majority of antipsychotic agents are not very affective in treating negative symptoms. Clozapine is reported to be somewhat effective for negative symptoms, however, several months of treatment are required and even then its effectiveness is controversial. Sigma-1 agonists and antagonists ap- pear to differentially affect cognitive dysfunction in animals, and their main action lies in the cortical and subcortical regions. These data suggest an important role for sigma receptors in antipsychotic drug action. A well characterized PET ligand is vital for effectively correlating clinical efficacy with the sigma-1 receptor occupancy of these drugs.
To summarize, the dopamine hypothesis of schizophrenia, dopaminergic hyperactivity in the nucleus accumbens is thought to be responsible for the positive symptoms (eg psychosis) of schizophrenia, whereas dopamine hypoactivity in the prefrontal cortex is thought to underlie negative symptoms (poverty of speech, cognitive dysfunction, social withdrawal). It is also believed that negative symptoms may be caused by a hypofunctioning of the NMDA ion channel, which in return causes a reduction in dopamine levels in the frontal cortex, thereby inducing negative symptoms. Several lines of research reveal a potential role of the human sigma-1 receptor in schizophrenia. In the brain, sigma-1 receptors modulate NMDA stimulated release of dopamine in the frontal cortex, striatum, nucleus accumbens, hippocampus and other brain regions. In vitro, sigma-1 agonists potentiate NMDA stimulated DA release, and sigma-1 receptor antagonists block the NMDA potentiation evoked by sigma-1 agonists. In vivo, under normal conditions, NMDA stimulated DA release would always be an active process. Endogenous sigma-1 agonists in theory would therefore stimulate the NMDA response, helping to maintain normal levels of dopamine in brain. However, in the case that sigma-1 receptors become understimulated, or reduced in number, the normal NMDA stimulated DA release evoked by sigma-1 receptor stimulation could be reduced (ie, an apparent NMDA hypofunction would occur).
Sigma Receptors in Substance Abuse
Substance abuse represents an augmenting social and health problem. There is an increasing understanding that substance abuse is a physiological disorder that requires pharmacotherapeutic intervention. Considerable effort has been devoted to the development of effective treatments for abuse disorders, and such research has led to some useful pharmacotherapeutic interventions. For example, methadone has been an effective medication and adjunct in treatment for heroin abuse, nicotine replacement has been useful in smokers, and naltrexone has provided help for alcoholics. At present, there are no suitable medications for the treatment of cocaine abuse [162] . A rational approach to develop a method for medication is to determine what cocaine does in the brain and then block or reverse that effect. Another strategy is the use of compounds that substitute for the primary actions of cocaine but have a longer duration of action paired with lower intrinsic abuse potential and lower toxic side effects. Amphetamine is another stimulant drug that produces euphoria and has a high abuse liability similar to cocaine.
Cocaine and amphetamine produce their behavioral and reinforcing effects via actions at the dopamine transporter. Cocaine binds to the dopamine transporter and inhibits reuptake of dopamine into presynaptic terminals, resulting in an increase in extracellular dopamine. Amphetamine also acts via the dopamine transporter and is transported into the terminals where it causes release of vesicular pools of dopamine into the cytoplasm and ultimately into the extracellular fluid. However, studies have also demonstrated that mice lacking dopamine transporters still respond to the rewarding properties of cocaine [163, 164] , demonstrating that additional mechanisms may also mediate the actions of cocaine. In addition to blocking the re-uptake of dopamine, cocaine also inhibits the re-uptake of serotonin and norepinephrine and binds to a number of neurotransmitter receptors [165] . Of the sites which cocaine interacts, the monoamine transporters, muscarinic receptors and sigma receptors are thought to be the most relevant. However, earlier investigations on serotonergic, noradrenergic, and muscarinic mechanisms have confirmed a role for these systems in the actions of cocaine, but suggested that they may be less optimal for drug development targets because of the limited efficacy and unfavorable side effects. Therefore, current thought has focused on targeting the sigma receptor.
The initial observation that cocaine, in addition to binding to the dopamine transporter, displays moderate but significant affinity for the sigma receptor was made by Sharkey and co-workers [166] . Cocaine displays a marked stereoselectivity for the binding to sigma receptors, with the (+)-isomer displaying lower affinity compared to the (-)-isomer ((+)-cocaine Ki = 16-26 µM, (-)-cocaine Ki = 2-7 µM) [167] . In addition, cocaine exhibits a 10-fold preference for the sigma-1 subtype (3 µM) compared to the sigma-2 subtype (30 µM), suggesting that most of cocaine's action occurs through interaction with the sigma-1 receptor. Cocaine thus interacts with the sigma-1 receptor at a concentration range that can be achieved in vivo.
Sigma receptors are known to modulate neurochemical systems that have been linked to the psychomotor and toxic effects of cocaine. For example, dopamine is an important neurotransmitter system that is involved in the psychomotor stimulatory actions of cocaine. The interaction between sigma ligands (Fig. 3) and modulation of dopamine has been demonstrated on several occasions [168] [169] [170] [171] .
Of particular interest is the description of the novel trishomocubanes 1 and 2 (Fig. 4) which displayed varied affinity for sigma-1 and sigma-2 receptors [172] . These ligands were shown to significantly enhance amphetaminestimulated [ 3 H]dopamine release from rat striatal slices and where identified as sigma-2 receptor agonists in these functional studies [173] . In behavioral studies, 1 has attenuated cocaine-induced locomotor activity in mice while 2 enhanced activity and was equally as potent as cocaine in inducing locomotor activity (Kassiou, unpublished results). These compounds are currently undergoing further investigation as potential treatments for substance abuse.
It has also been shown that sigma receptor ligands modulate dopamine neuronal activities [174] [175] [176] [177] [178] and block the effects of many hallucinogens and stimulants [178, 179] suggesting that sigma receptors may be used to antagonize the psychotropic effects of amphetamine and cocaine, since these drugs act though the dopamine system. The sigma-1 antagonists, BMY 14802, DuP 734, rimacazole and NPC 16377 all dose dependently reduce cocaine-stimulated locomotor activity in rodents. Furthermore, DuP 734 and NPC 16377 were also potent in blocking amphetamine-stimulated locomotor activity in mice further suggesting a role of sigma receptors in these activities. The involvement of sigma receptors, particularly the sigma-1 subtype, has been shown to be involved in numerous other cocaine-induced stimulant effects in rodents [167] . This has been demonstrated by determining the effect of various sigma-1 receptor ligands on several pharmacological and behavioral measures associated with cocaine, including locomotor activity, stereotyped behaviors, sensitization, and place-preference. The ligands used have been sigma-1 receptor antagonists of many different chemical classes, including those mentioned above and also BD 1047, LR 172, and NE 100. Several sigma-1 receptor antagonists, examples being BD 1047 and LR 172, have also been shown to attenuate cocaine-induced lethality [180, 181] . Mice were pre-treated with sigma-1 antagonists, blocking the ability of cocaine to interact with sigma receptors and reducing its toxic effects. Other studies have demonstrated that when mice are treated with sigma-1 receptor antagonists following cocaine overdose, lethality is significantly attenuated [182] .
The descriptions above are not intended to be an exhaustive list of ligands used in these types of experiments, but to clearly demonstrate that the sigma-1 receptor represents a novel target for the development of effective therapies against cocaine abuse. The ability of sigma receptors ligands to attenuate various cocaine-induced behaviors is thought to result from their ability to mediate the actions of cocaine at different levels, including a possible direct action at the receptor level, by competing with cocaine for binding at sigma receptors, and modulation of downstream neurotransmitter systems, particularly dopamine transmission. More recently the sigma-1 receptor antagonist BD 1063 prevented cocaine- 
Ki (sigma-1) = 11 nM Ki (sigma-2) = 370 nM (1) induced changes in gene expression, indicating a possible third mode of action [183] . Mice were treated with either saline and cocaine, BD 1063 and cocaine, or BD 1063 and saline. The dose of cocaine and BD1063 administered was 10 mg/kg, i.p. and 30 mg/kg i.p, respectively. The expression of 1176 genes in the brains of these animals where then profiled using cDNA microarrays. The animals that were exposed to cocaine had significant (greater than five-fold change) up-regulation of 20 genes and down-regulation of 16 genes. While animals treated with BD 1063 prevented cocaine-induced changes in three genes: fos-related antigen 2 (fra-2), G-protein coupled receptor 27, and ataxia telangiectasia murine homolog. The significance of these observations still requires investigation, however, cocaine is also known to stimulate other fos-related transcription factors [184] .
Based on the above observations, it has been proposed that the sigma receptor and sigma-1 receptor antagonists represent a novel target system for the treatment of cocaine abuse. The use of PET imaging can provide useful information on both the changes in sigma receptor functionality as a result of cocaine use as well as provide pharmacokinetic and pharmacodynamic information on newly developed sigma ligands. These types of PET imaging studies will assist in the evaluating the full potential of sigma receptors as a potential therapeutic site.
Sigma Receptors in Depression
Synthetic and steroidal sigma-1 receptor agonists exhibit antidepressant-like effects in several rodent models of depression. Many recent reviews are available [185] [186] [187] [188] [189] [190] [191] [192] . As one example, in mice subjected to forced swimming, the sigma-1 agonists igmesine, (+)-SKF-10,047 and DHEAS shortened the immobility time [193, 194] however, these effects were blocked by the sigma-1 receptor antagonists BD1047 and progesterone. Furthermore, in adrenalectomized/castrated mice, the effects of igmesine and DHEAS were significantly enhanced. These data support an antidepressant response associated with sigma-1 receptor activation from both synthetic and steroid based agonists.
Su et al. have hypothesized that sigma-1 receptors, at least in part, are intracellular amplifiers creating a supersensitized state for signal transduction in the biological system [195] . Sigma ligands may act to produce a rapid modulation of the serotonergic system in the dorsal raphe nucleus and the glutamatergic system in the hippocampus. The antidepressant-like effect induced by sigma-1 receptor agonists may involve intracellular Ca(2+) mobilization. Finally, growth factor-induced neurite outgrowth is mediated through sigma-1 receptors, suggesting a role in neuroplasticity.
In humans, igmesine (JO1783), OPC-14 523 and SA4503, have recently been developed as sigma-1 agonists and are found to have antidepressant-like activity with fewer side effects [196] . Among selective serotonin reuptake inhibitors, fluvoxamine has proven effective in one study of psychotic depression, without the need of any other antipsychotic agents. It has been proposed that the apparent efficacy of fluvoxamine in psychotic major depression may be related to its high affinity binding to the sigma-1 receptor [197] . Finally, the sigma-1-selective medication igmesine (200 mg) has recently showed promising results in depressed patients [190] .
Following from the studies in rodents noted above, much attention has also been placed on the beneficial effects of DHEA and DHEAS (the sulfate of DHEA) in patients with depression. Serum DHEAS is secreted from the adrenal glands, and is thought to be a precursor of sex steroids. DHEAS has recently been shown to have direct physiological properties associated with memory, stress, anxiety, sleep and depression [186, [198] [199] [200] [201] [202] [203] [204] [205] [206] . Recently, DHEA has been proposed as an alternative or adjunct to the antidepressants currently available, perhaps providing benefit to treatmentresistant depressed patients. Heuser et al. found parallel increases in diurnal DHEA and cortisol plasma concentrations in depressed patients with important implications for the regulation of the hypothalamus-pituitary-adrenocortical system [207] and they rationalized that, DHEA treatment should provide benefit to chronically stressed depressed patients. Fabian et al. found that a decrease in plasma DHEA and DHEAS is related to remission of depression rather than to a direct drug effect on steroids, and that nonremitters exhibited no change in hormone concentrations [198] . Schmidt et al. evaluated the efficacy of DHEA as a monotherapy for midlife onset depression in a double-blind, randomized, placebocontrolled, crossover treatment study. Forty-six individuals 45 to 65 of age with midlife-onset major or minor depression were studied [208] without receiving concurrent antidepressant medication. After six weeks of DHEA administration, a significant improvement in the 17-Item Hamilton Depression Rating Scale (HDRS) and the Center for Epidemiologic Studies Depression Scale rating were found when compared with both baseline and 6 weeks of placebo treatment. The authors conclude that DHEA may provide an effective treatment for midlife-onset major and minor depression.
Maayan et al. studied treatment resistant depressed patients receiving ECT to find that pretreatment and post-ECT levels of cortisol [209] , DHEA, and DHEAS are significantly higher in these patients compared to control subjects. However, DHEAS levels in responding patients increased after completion and were higher compared to pretreatment measures. In addition, patients defined as ECT nonresponders (change in HDRS < 30% from before treatments) exhibited initial significantly higher (> 2 SD of the mean from controls) baseline DHEAS levels compared with ECT responders. These authors conclude that significantly elevated basal DHEAS levels are associated with resistance to ECT and may serve as a potential predictive marker of nonresponsiveness to ECT in depressed patients.
The documented beneficial effect of DHEA administration in depressed patients might result from its sigma-1 receptor-mediated enhancement of noradrenaline and serotonin neurotransmission, antiglucocorticoid effects, and cognition enhancing effects [191] . To date, no postmortem studies have been made to determine if changes in sigma-1 receptor densities exist in patients with depression. It is clear that the use of an effective sigma-1 receptor radioligand may allow one to evaluate the status of these sites in newly diagnosed depressed patients and allow the determination of sigma-1 receptor occupancy by DHEA and other sigma-1 binding medications in human trials.
F. SIGMA RECEPTORS IN CARDIOLOGY
Recent studies have been attempting to elucidate the function of sigma receptors in the heart [210] [211] [212] [213] [214] . Zhang and Cuevas found that sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. They hypothesized that sigma-1 receptors are directly coupled to K(+) channels in intracardiac neurons and that activation of sigma-1 receptors depresses the excitability of intracardiac neurons and is thus likely to block parasympathetic input to the heart [210] . Several groups have shown that cardiac myocytes possess sigma receptors and that nanomolar concentrations of the prototypical sigma ligands (+)-PPP, pentazocine or haloperidol exert effects on contractility, calcium ion transients and fluxes in these cells [215] [216] [217] [218] . The cardiac effects of sigma receptor ligands include elevation of inositol 1,4,5-triphosphate production in rat cardiac myocytes, and an increase in the incidence of spontaneous twitches and evoked potentiation of contraction [218] . The activation of sigma-1 receptors leads to an increase in the ventricular fibrillation threshold in rat models of post-infarction cardiosclerosis and in the immobilization stress-induced model [219] . Blockade of sigma receptors using the antagonist DuP 734 reversed the decrease in ventricular fibrillation threshold in the rat models of postinfarction cardiosclerosis and stress. Furthermore, treatment with DuP 734 (1 mg.kg i.p.) returned the ventricular fibrillation threshold to levels seen in control animals. The efficacy of the sigma antagonist DuP 734 in the post-infarction cardiosclerosis model was significantly stronger than that seen using epsilon and kappa-opioids. However, in the stressed rat model the effect of DuP 734 was not significantly better than kappa-opioid agonist spiradoline (8 mg/kg i.p.), but was superior to the mu-opioid agonist DALDA (0.1 mg/kg i.v.). In another study, DuP 734 administration augmented reperfusion systolic dysfunction of the myocardium and prevented post-ischemic contractures, cardiac cell lesions and activation of cardiac sigma-receptors to prompt an augmentation of tolerance to the reperfusion damage [220] .
Cocaine use has been associated with a large abrupt and transient increase in the risk of myocardial infarction in patients with and without underlying coronary atherosclerosis [221] . Wilbert-Lampen et. al. [222] stated that the cocaineassociated vascular events in the myocardium cannot be completely explained by adrenergic stimulation. They demonstrated cocaine induced increases in endothelin-1 release in vitro and in vivo. Endothelin-1 levels in plasma (22.7 ± 5.6 versus 7.3 ± 0.8 pmol/L) and urine (41.5 ± 10.1 versus 12.7 ± 3.8 pmol/L) of cocaine-intoxicated patients were significantly increased over controls [222] . In addition, in vitro studies with porcine aortic endothelial cells including treatment with cocaine and sigma receptor antagonists were performed. These studies showed that cocaine significantly increased endothelin accumulation above baseline from 3 to 24 hours, and that the endothelin release rate was dose dependent. Neither haloperidol nor DTG induced significant changes in basal endothelin rates. However, both drugs abolished all cocaine effects on the release of endothelin, which indicated a clear role for sigma receptors in the regulation of endothelin release in the heart.
Researchers at the Cardiac Gene Unit [223] at Toronto University (Toronto, Canada) have identified genes for over 100 receptors expressed in the human cardiovascular system including endothelin, steroid and sigma receptors. Using a very selective sigma-1 receptor radioligand, [ 18 F]FPS, Waterhouse and Collier have demonstrated specific binding to sigma-1 receptors in many organs in rodents, including the heart (see Fig. 5 ) [224] .
Taken together, the above information highlights an important yet largely unexplored area of research to examine the normal biological function and therapeutic potential of cardiac sigma receptors. Clearly this is one exciting and critical area of research that should be further explored.
G. SIGMA RECEPTORS IN ONCOLOGY
Another indication for imaging sigma receptors in drug development and treatment follow-up lies in the field of oncology. Applications of PET and SPECT in the field of oncology are well accepted. These non-invasive imaging modalities are currently unsurpassed techniques regarding their sensitivity to normal and aberrant biochemical processes in living subjects. While these techniques do not fully replace Fig. (5) . Effect of selected steroids (1 µM) on the binding of [F-18] FPS in rat heart membranes *p < 0.02 **p < 0.006. computed tomography (CT), magnetic resonance imaging (MRI), and x-radiography, they often provide complementary information that may be critical in clinical decision making. Example applications include identifying cancerous lymph nodes, differentiating between post-treatment tissue effects and recurrent tumors, and monitoring the effectiveness of specific types of anti-cancer treatments. [ 18 F]Fluorodeoxyglucose ([ 18 F]FDG), a fluorinated derivative of glucose and the most widely used PET tracer in oncological examinations and research, accumulates in proportion to the local rate of glucose metabolism [225] [226] [227] [228] [229] [230] [231] . Since tumor cells are often characterized by high metabolic demand, uptake of this tracer is typically higher in tumors than in most normal tissues. It is generally accepted that the increased [
18 F]FDG accumulation in cancer cells is due to increased densities of glucose transporters and phosphorylating enzymes [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] . In addition, enhanced FDG uptake may be due to relative hypoxia in tumor masses, which activates the anaerobic glycolytic pathway [236, 239] . The signal may not be entirely specific since tumor-associated macrophages also utilize high levels of glucose, leading to increased signal in tumors but also an increased nonspecific signal. [233, 240, 244, 246, [248] [249] [250] . This is due to many well characterized physiological and biochemical factors related to the uptake mechanisms of [ 18 F]FDG. First, muscle largely utilizes glucose for energy and as a result [ 18 F]FDG localizes extensively in the muscle and heart. High heart and muscle activities sometimes interfere with the visualization of diseased lymph nodes and metastases, especially in the thorax, and also serve as factors in standard uptake value (SUV) variability. Therefore, imaging agents exhibiting lower and less variable cardiac and muscle activity are desired. For the past 20 years, efforts to develop tumor imaging tracers not based on glucose metabolism have been made. Several receptor targeted PET and SPECT radiopharmaceuticals have been developed for imaging cancer patients, including diagnostic and prognostic applications as well as monitoring of anticancer drug effectiveness. In addition, some tracers have been developed to monitor cancerassociated processes, such as cellular proliferation, apoptosis and angiogenesis. To date, no agent can be as universally applied as [ 18 F]FDG since tumor cells are very heterogeneous and often the target sites are not expressed, or do not correlate well with drug effects. Sigma receptors are considered an appropriate target due to their high expression in most known human cancers. We review here the state of the art in three areas of oncology, including the study of lung, prostate and breast cancer, where it is thought that imaging sigma receptors might provide a significant advance.
Lung Cancer. Lung cancer is the leading cause of cancerrelated death in both men and women in most Western countries [251] . Although the 5-year survival rate has doubled since the 1960s, it remains low compared to that of many other cancers. Patient history, physical examination, laboratory blood tests, and disease-associated symptoms assist in initial staging. Tumor stage remains the strongest prognostic factor and is a key parameter in treatment decision-making [251] .
Prostate Cancer. Prostate cancer is a leading cause of cancer related death in men. Treatment goals for men with advanced prostate cancer include prolonging survival, delaying symptoms due to disease progression, improving and maintaining quality of life, and reducing treatment related morbidity. The accurate staging of prostate cancer is mandatory to allow selection of appropriate therapies. In addition, whenever PSA levels increase it is critical to accurately pinpoint the location of cancer recurrence or metastatic spread. Visualization of prostate cancer with PET using [
18 F]FDG as a radiopharmaceutical is limited by the low uptake of FDG in the primary tumor, and to a lesser extent by high bladder activities [252, 253] . It is well documented that more effective PET radiopharmaceuticals are required for this indication, and several laboratories are working to develop improved agents [55, [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [265] [266] [267] [268] . [269] [270] [271] [272] [273] [274] [275] , and one class of nonselective iodine-123 labeled sigma receptor ligands based on a benzamide structure [55, 254] . The real promise of [ 11 C]acetate PET relative to other imaging techniques requires further investigation, with special focus on lymph node involvement, early localization of recurrence and possible noninvasive differentiation between prostate cancer, prostatis and benign prostate hyperplasia (BPH) [256, 257] .
Breast Cancer. Imaging primary breast cancer can be accomplished by several methods. Mammography is the most widely used technique because of its excellent diagnostic performance, patient compliance, and cost-effectiveness ratio. Other techniques such as computer-aided diagnosis (CAD), power Doppler ultrasound, magnetic resonance imaging (MRI), and nuclear based imaging with [ 18 F]FDG PET are also under evaluation [276] . The role of PET in the management of patients with breast cancer is still evolving. For assessing primary lesions, it is sometimes possible with PET to detect tumors that are missed by mammography and other standard methods. Several PET and SPECT radiotracers have been evaluated as breast tumor imaging agents in pre-clinical and clinical studies [13, 49, 53, 56, 57, 63, 255, [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [287, 294] are examples of tracers in preliminary stages of evaluation. Other types of tracers are in various stages of development and testing [13, 49, 53, 57, 283, 284, 291, 295] . At this time, no agent has proven to be sufficiently accurate and specific in a clinical trial to be confirmed as a useful clinical tool. Therefore, there is an established need to develop more effective imaging agents for visualization of breast malignancies, especially for small lesions (< 5 mm diameter), as well as those that might provide prognostic information.
In summary, the goals of cancer imaging are multiple and include the early detection of primary tumors, correlation of imaging results with other clinical parameters to assess disease biology, accurate staging, and monitoring of treatment effectiveness. The general advantage of nuclear-based imaging methods is that tumor-seeking radiopharmaceuticals accumulate in cancer lesions, making mammography and PET fundamentally different from other radiological techniques based solely morphological alterations. The combination of PET or SPECT imaging with the more classical imaging technologies such as CT or MRI often provide a much higher sensitivity that when these modalities are used alone. While [
18 F]FDG currently remains a superior imaging agent for many types of malignancies, in many cases improvements in sensitivity and specificity are still required to prevent invasive and costly procedures resulting from false positive scans. In addition, imaging in patients with diabetes is often not reliable when [
18 F]FDG is used, and therefore new agents are required for such cases. Improved imaging tools to assess treatment response more accurately than [ 18 F]FDG, or even a priori predict responsiveness of malignant tumors to chemotherapy, are still desired and even required for certain malignancies. In addition, an imaging agent that could provide some prognostic information would be most beneficial.
Sigma-1 Receptors as Tumor Associated Markers
Both sigma receptor subtypes are expressed in high densities in a wide variety of human tumors [12, 13, 54, 254, [296] [297] [298] [299] [300] [301] . For the sigma-1 receptor specifically, as examples these include cancers of the breast (except MCF-7 cells), lung (small cell and non-small cell lung cancer cells), colon, ovaries and prostate (androgen dependent and androgen independent cancers) and brain [28, 118, [302] [303] [304] [305] [306] [307] [308] . The reported Bmax range for these cancer cell lines is 180 -6839 fmol/mg protein (most are well above 1000 fmol/mg protein), including those of rodent and human origin. A recent and potentially important finding is that, in human breast cancer biopsies, the expression of sigma-1 receptors correlates positively with bcl-2 expression and inversely with progesterone receptor expression [301] . Bcl-2 is a protooncogene whose magnitude of expression has been found to correlate with ER positive status and favorable prognosis in breast cancer patients [309, 310] . Therefore, it was suggested by Simony-Lafontaine et al., that sigma-1 receptors might prove a useful prognostic marker in breast cancer [301] .
Due to their high expression in cancer cells, along with their suggested roles in processes associated with cellular proliferation and apoptosis, several groups have explored the potential of sigma-1 receptor agonists as anti-cancer agents [300] . As an example, Berthois et al. found that nanomolar concentrations of the mixed sigma-1/sigma-2 binding compound SR31747A dramatically inhibited cell proliferation in both hormone-responsive and hormone-unresponsive cancer cell lines [311] . However, these findings are controversial since in the majority of such studies the doses required to inhibit cellular proliferation were high, leading to the possibility of the involvement of other sites in the antiproliferative action of these compounds. The known high expression of sigma-1 receptors in many malignancies has prompted several groups to develop candidate PET and SPECT radiotracers for these sites.
Acute pre-clincial toxicity evaluations and rodent-based dosimetry studies have been performed [312] , and an IND application approved supporting [ 18 F]FPS PET imaging studies in humans. As discussed above sigma-1 receptor density is significantly increased in many human malignancies, including cancers of the breast, lung and prostate. [52, 313, 314] . [ 123 I]HEPIE showed high update in small cell lung cancer xenografts (see Fig. 6 ) [315] . To date for oncology studies, [ 18 F]FPS has been characterized in two mouse tumor models; the B16 melanoma xenograft model where it proved superior to [ 123 I]HEPIE, and the transgenic MMTV mouse model of breast cancer (see Fig. 7 ) [313] . 
H. OTHER ORGAN AND SYSTEMS
In the eye, sigma receptors have been located in the lacrimal gland, retina, iris-ciliary body, cornea and lens [36, 316, 317] . The effect of sigma agonist (+)-pentazocine was to lower the intraocular pressure, protection of retinal ganglion cells and modulation of cell growth and pigmentation in the lens. Duncan and Wang showed the neuroprotective effects of sigma agonists and have proposed the opposite effect for sigma antagonist. This corollary effect has been hinted at by the impairment of cell growth across the posterior capsule by the relatively low concentrations of antagonists. Evidence from binding studies have suggested that the sigma-2 receptor is also present in the retina.
Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model [318] . It is known that cocaine is associated with an increased risk for, and progression of, clinical disease associated with human immunodeficiency virus (HIV) infection. Cocaine has been shown to mediate immunosuppressive effects by activating sigma-1 receptors in immune cells in vitro and in vivo. Consistent with these reports, a selective sigma-1 antagonist, BD1047, blocked the effects of cocaine on HIV replication in the huPBL-SCID mouse. Roth et al. suggested that systemic exposure to cocaine can enhance HIV infection in vivo by activating sigma-1 receptors and by modulating the expression of HIV coreceptors.
Gannon et al. [319] reported that SR31747A (which is known to bind to the sigma-1, sigma-2, and emopamilbinding proteins) is a novel immunomodulator that down regulates nitric oxide and IL-10 protein and mRNA expression. It has also been shown to exhibit immunosuppression and is able to inhibit cell proliferation both in vitro and in vivo [320] .
I. CONCLUSIONS
Both established sigma receptor subtypes play a role in a multitude of cellular functions as well as participate in a variety of pathological conditions. While the study of sigma receptors is still in its early stages compared to better characterized receptor systems, the information collected thus far implicates these proteins as valuable targets for drug development research in several diverse fields including oncology, cardiology, psychiatry, neurology, ophthalmology and immunology. Thus, development of imaging methods for visualization and quantification of these proteins in living individuals would have widespread and significant impact on many clinical fields and patient populations. In addition, such tools would aid in sigma receptor drug development in various settings. Promising radiotracers for both established sigma receptor subtypes is thus critically needed, and the availability of effective sigma-1 receptor selective radiotracers is expected in the very near future. 
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